CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 256 enrolled
Drug / intervention
RX-10045drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02329743
NCT02329743Phase 2Completed
CompareCT.gov

A Multicenter, Double-Masked, Parallel-Group, Vehicle-Controlled Study to Assess the Efficacy and Safety of RX-10045 Nanomicellar Ophthalmic Solution for Treatment of Ocular Inflammation and Pain in Subjects Undergoing Cataract Surgery

A.T. Resolve SARL·interventional·Posted Jan 1, 2015·Updated Feb 20, 2019

In Brief

A Phase 2 clinical trial evaluating RX-10045 for Inflammation and 2 related conditions. Completed, enrolled 256 participants across 1 site.

Detailed Summary

The primary objective of this study is to assess the efficacy and safety of 2 concentrations of RX-10045 ophthalmic solution, 0.05% and 0.1%, compared to placebo for the treatment of ocular inflammation and pain in subjects undergoing cataract surgery.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInflammation, Pain, Cataract
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJan 1, 2015
Enrollment StartDec 1, 2014
Primary CompletionSep 1, 2015
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 11.5 years ago

Interventions

RX-10045drug

topical therapy